- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06209151
Intensive Care Unit Procedure Related Infections
Procedure Related Infections in Intensive Care Unit
Objectives: To identify the rate and predictors of procedure related infection, the most causative organisms and the effect on ICU stay and in hospital mortality. To show the validity of NEW score in predicting mortality.
Methods: Prospective observational study of 1040 patients admitted to the ICU without any signs of infection. All patients were subjected to one or more of the most used procedures in ICU (Intubation & mechanical ventilation, Central line insertion and Urinary catheterization) for at least 48 hours. Then, they were followed for any signs of infection either clinically or laboratorial.
Study Overview
Detailed Description
AIM OF THE WORK
- To identify the rate and predictors of procedure related infections in ICU after application of all preventive measures and to identify most causative organisms.
- Identification of the effect of procedure related infections on ICU stay and in hospital mortality.
- To study the validity of NEW score in predicting mortality in comparison to APACHE II score .
PATIENTS AND METHODS
Study design:
This was a prospective observational study carried out at medical and cardiac intensive care units (ICUs) of 3 secondary and tertiary care hospitals from July 2022 to June 2023 and included 1040 patients.
Inclusion criteria:
All consecutive adult patients admitted to ICU who had been subjected to the following procedures:
- Urinary catheterization.
- Central venous catheter (CVC) insertion.
- Endotracheal intubation and mechanical ventilation.
Exclusion criteria:
- Patients with evidence of infection prior to ICU admission.
- Procedures done before ICU admission.
All patients were subjected to the following assessment:
A) On admission:
- The acute physiology and chronic health evaluation II (APACHE II) score.
- New early warning score 2 (NEWS2): NEWS ranges from 0, indicating the lowest severity of illness, to a maximum value of 20.
- Detailed history including age, sex, medical history.
- Complete clinical examination.
- Chest x-ray.
B) ICU stay:
• Laboratory investigations include Complete blood count (CBC), C reactive protein (CRP), renal and liver chemistry after 2, 4, 6, 12, 18 and 24 days.
Blood, urine and sputum cultures if infection was suspected.
• Chest x-ray if chest infection suspected.
C) FOLLOW UP :
- Length of mechanical ventilation
- Length of ICU stay
- Length of hospital stay
- Morbidity & mortality
Primary outcomes:
- Identification of rate and predictors of procedure related infections.
- Identification of the most causative organisms.
Secondary outcomes:
- Identification of the effect of procedure related infections on ICU stay and in hospital mortality.
- The validity of NEW score in predicting mortality
Definitions:
Ventilator associated pneumonia (VAP): was defined as pneumonia occurring >48 hours following endotracheal intubation when a new or progressive lung infiltrates, consolidation, or cavitation on chest X-ray develops in a patient with:
- New onset of purulent bronchial secretions with leukopenia (white blood cells <4×109/L) or leukocytosis (>12×109/L)
- Core temperature ≥38.5°C or ≤36°C without other cause, significant positive culture from blood, or endotracheal aspirate, broncho-alveolar lavage (BAL), or culture from another relevant site of infection [10].
Catheter associated urinary tract infection (CAUTI): A patient must meet all three criteria below:
- Patient had an indwelling urinary catheter that had been in place for >2 days on the date of event (day of device placement=day 1) and was either present for any portion of the calendar day on the date of event or removed the day before the date of event.
Patient has at least one of the following signs or symptoms:
fever (>38.0°C); suprapubic tenderness; costovertebral angle pain or tenderness; urinary urgency; urinary frequency; dysuria.
- Patient has a urine culture with no more than two species of organisms identified, at least one of which is a bacterium of ≥105 cfu/mL.
Central line associated blood stream infection (CLABSI): A patient with a central venous catheter who has a recognized pathogen isolated from one or more blood cultures after 48 h of catheterization; or with the same skin commensals cultured from two or more blood cultures drawn on separate occasions; the pathogen is not related to an infection at another body site; and the patient has one or more of the following signs or symptoms: fever (≥38⁰c), chills, or hypotension, CLABSI was confirmed.
Statistical analysis SPSS 26.0 (SPSS Inc., an IBM Company, Chicago, IL) was used to perform the data analyses.
Baseline differences among rates were analyzed using the chi-square test for dichotomous variables and a t-test for continuous variables. 95% confidence intervals (CIs) and P values were determined for all outcomes.
Outcomes measured during the surveillance period included the incidence of overall DAIs, VAPs, CAUTIs, and CLABSIs.
DAI rates per 1,000 device-days were calculated by dividing the total number of DAIs by the total number of specific device-days and multiplying the result by 1,000 (16).
Device utilization ratios were calculated by dividing the total number of device-days by the total number of patient-days.
Device-days are the total number of days of exposure to the device (ventilator, urinary catheter, or central line) by all of the patients in the selected population during the selected time period.
Patient-days are the total number of days that patients are in an ICU during the specified time period.
Discrimination of scoring systems was assessed using the receiver operating characteristic (ROC) curve analysis for calculating the sensitivity and specificity of each score and the corresponding area under the ROC curve.
Correlations between quantitative variables were done using Spearman correlation coefficient.
Crude excess mortality of DA-HAI equals crude mortality of ICU patients with DA-HAI minus crude mortality of patients without DA-HAI.
Crude excess LOS of DA-HAI equals crude LOS of ICU patients with DA-HAI minus crude LOS of patients without DA-HAI.
Qualitative variables were presented as number and percentage (%).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt, 11345
- Cairo University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
All consecutive adult patients admitted to ICU who had been subjected to the following procedures:
- Urinary catheterization.
- Central venous catheter (CVC) insertion.
- Endotracheal intubation and mechanical ventilation.
Exclusion Criteria:
• Patients with evidence of infection prior to ICU admission.
- Procedures done before ICU admission.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of rate and predictors of procedure related infections
Time Frame: 3 months
|
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
1. Identification of the effect of procedure related infections on ICU stay and in hospital mortality.
Time Frame: 3 months
|
2. The validity of NEW score in predicting mortality.
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ahmed Mowafy, MD, Cairo University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Kasr alainy school of medicine
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections
-
International Centre for Diarrhoeal Disease Research...Centers for Disease Control and PreventionNot yet recruitingMeasles | Rubella | Cholera | Typhoid
-
MJM BontenJanssen Research & Development, LLC; Innovative Medicines InitiativeCompletedE.Coli InfectionsUnited States, United Kingdom, Canada, France, Germany, Italy, Japan, Spain
-
PfizerCompletedGroup B Streptococcus InfectionsUnited States, South Africa, United Kingdom
-
GlaxoSmithKlineActive, not recruitingInfections, MeningococcalFinland, Poland, Spain, United Kingdom, Germany, South Africa, Dominican Republic, Israel, Honduras
-
PfizerCompletedInfections, MeningococcalAustralia, Canada, Czechia, Panama, South Africa, Turkey
-
GlaxoSmithKlineCompletedInfections, MeningococcalFinland
-
PfizerCompletedInfections, MeningococcalPhilippines
-
GlaxoSmithKlineCompletedInfections, MeningococcalUnited States, Finland, Poland
-
GlaxoSmithKlineCompleted
Clinical Trials on monitor signs of infection
-
Assumpta Solome NantumeDLR German Aerospace Center; Academic Model Providing Access to Healthcare...RecruitingNewborn Morbidity | Newborn ComplicationKenya
-
Neopenda, PBCCenter for Public Health and DevelopmentCompletedNewborn Morbidity | Newborn ComplicationKenya
-
Northwestern UniversityAnn & Robert H Lurie Children's Hospital of ChicagoCompletedAllergy | Asthma in ChildrenUnited States
-
Lady Davis InstituteCarebook Technologies Inc.UnknownVascular Diseases | Coronavirus | Respiratory Disease | Cardiac Disease
-
Malaria ConsortiumUNICEF; Ministry of Health, Ethiopia; La Caixa FoundationTerminatedPneumonia ChildhoodEthiopia
-
AIDAR Health, Inc.MAXIS, LLCWithdrawn
-
UConn HealthUnited States Department of Defense; Substance Abuse and Mental Health Services... and other collaboratorsCompleted
-
Sohag UniversityCompletedSonographic Signs of Gouty Arthritis in Diagnosed and Suspected PatientsEgypt
-
The Cleveland ClinicWellflix, Inc.CompletedHeart Failure; With DecompensationUnited States
-
University Hospital, BordeauxCompleted